AI-Powered Research

Psychotic disorder patients: a DSM-IV or 5 classification of schizophrenia, schizophreniform disorder, schizoaffective disorder (both depressive and bipolar types), psychosis not otherwise specified (or other unspecified psychotic disorders), major depressive disorder with psychotic features, bipolar disorder with current psychotic features or a history of psychotic features and psychosis during the peripartum period (8 weeks after giving birth). DSM-IV or DSM-5 diagnosis will be clinician-rated or based on semi-structured interviews (i.e. the Semi-structured Clinician Interview for DSM Disorders, SCID).

Affective disorder patients: a DSM-IV or 5 classification of unipolar depressive or bipolar disorders without psychotic features. DSM-IV or DSM-5 diagnosis will be clinician-rated or based on semi-structured interviews (i.e. the Semi-structured Clinician Interview for DSM Disorders, SCID).

Exclusion Criteria

Patients with psychotic or affective disorders
Subjects meeting any of the following criteria will be excluded from participation in this study:

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CSF constituents:<br /><br>-Autoantibodies to CNS receptors.<br /><br>-A panel of cytokine, chemokine and growth factor levels.<br /><br>-MiRNA levels. <br /><br>-Neurotransmitter concentrations (including GABA, glutamate and all major amino acids).<br /><br>- Plasma: Plasma levels of the CSF constituents mentioned under primary parameters.<br /><br>- Genetic assessments: To unravel the contribution of genetic variation to the quantitative phenotypes under investigation here, and thereby potentially aid in the identification of genetic variation underlying psychosis, a hypothesis-driven genetic approach will be adopted.<br /><br>-To link biochemical and genetic data to the behavioral level, we will have participants fill out questionnaires assessing a range of behavioral traits, as mentioned below. <br>

Secondary Outcome Measures

Name	Time	Method
- Plasma: Plasma levels of the CSF constituents mentioned under primary parameters.<br /><br>- Genetic assessments: To unravel the contribution of genetic variation to the quantitative phenotypes under investigation here, and thereby potentially aid in the identification of genetic variation underlying psychosis, a hypothesis-driven genetic approach will be adopted.<br /><br>-To link biochemical and genetic data to the behavioral level, we will have participants fill out questionnaires assessing a range of behavioral traits, as mentioned below. <br>